A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial



Summary

This phase 1 clinical trial investigates the safety and immunogenicity of a peptide vaccine targeting the cytomegalovirus (CMV) antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma. These cancers frequently express CMV. The vaccine aims to stimulate an immune response against CMV-expressing tumor cells. The trial focuses on evaluating the vaccine’s side effects and ability to induce T-cell responses against pp65. Preliminary results likely assess dosage, administration schedule, and the observed immune response in the study participants, laying the groundwork for future efficacy trials.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!